HomeAI · summaries
Storia in 5 fonti
Novo Nordisk trial ‘own goal’ sparks flurry of analyst downgrades
Analysts raced to cut price targets on an already struggeling Novo Nordisk stock following disappointing trial results for its weight loss candidate CagriSema.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly's in trial
Novo Nordisk stock fell as much as 10% Monday after it said its next-generation weight loss drug didn't meet its primary target.
- ·
ansa.it
Novo Nordisk scivola in Borsa (-8%) dopo dati deludenti per Cagrisema - Notizie - Ansa.it
Seduta pesante per la multinazionale danese del farmaco Novo Nordisk dopo aver reso pubblici dati deludenti sulla sperimentazione della terapia antiobesità Cagrisema. (ANSA)
- ·
cincodias.elpais.com
Novo Nordisk vuelve a hundirse en Bolsa al fallar los ensayos de su nuevo medicamento contra la obesidad
La acción cae hasta un 16% y se deja ya un 75% desde mediados de 2024. El grupo danés se queda por detrás de su rival estadounidense Eli Lilly
- ·
theguardian.com
Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’
Novo Nordisk’s shares fall sharply after testing of CagriSema falls short of investors’ expectations
- ·
ft.com
Novo Nordisk shares drop 15% after poor trial results for new obesity drug
Once-a-week injection achieved less weight loss than rival treatment
- ·
Eli Lilly's lead in the obesity race gets wider after another win against rival Novo Nordisk
Lilly shares rose more than 4% Monday, while rival Novo Nordisk tanked.
- ·
Novo Nordisk trial ‘own goal’ sparks flurry of analyst downgrades
Analysts raced to cut price targets on an already struggeling Novo Nordisk stock following disappointing trial results for its weight loss candidate CagriSema.
- ·
Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss
The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound.
- ·
These 4 charts show the scale of Novo Nordisk's woes
Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.